← Leaderboards
Jarrod Longcor
Cellectar Biosciences, Inc.
$1,997,244
Attributed
$3,994,487
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2021–23$2M$1.5M$1M$500K$0
'21
'22
'23
Funding mix
By agency
NIH$3,994,487 · 2
By mechanism
R44$3,994,487 · 2
Top collaborators
- Laurence Reilly4 shared
- John Friend1 shared
Most similar at Cellectar Biosciences, Inc.
Same institution · by research overlap
- Laurence Reilly$1,615,704
- John Friend$381,540
Others in their field
Other Emerging Leaders on “Neoplastic Cell”
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Tina Garyantes · Linnaeus Therapeutics, Llc$6,999,960
- Zachary Scott Morris · University Of Wisconsin-Madison$6,108,830
- Samuel F Bakhoum · Weill Medical Coll Of Cornell Univ$6,006,178
- Gordon M Ringold · Quadriga Biosciences, Inc.$5,755,369
- Himisha Beltran · Dana-Farber Cancer Inst$5,409,904
Research focus
Neoplastic CellPharmaceutical PreparationsIntravenous AdministrationMembrane MicrodomainsNormal Tissue MorphologyOpen LabelExposure ToI131 IsotopeClinical TrialsMedicalNormal CellCell SurvivalDoseNovel TherapeuticsClinical DevelopmentEfficacy EvaluationFda ApprovedHalf-LifeCancer CellAnalogCancer TypeMalignant NeoplasmsCell ProliferationPhospholipid Ethers
Grant awards (5)
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$965,201
R44 · FY2023 · CA
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$475,806
R44 · FY2023 · CA · contact PI
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade Glioma$1,034,797
R44 · FY2022 · CA
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$755,603
R44 · FY2022 · CA · contact PI
An Open-Label, Multicenter, Phase 2/3 Efficacy and Safety Study of a targeted radiotherapy in Patients with Relapsed or Refractory Waldenstroms Macroglobulinemia$763,080
R44 · FY2021 · CA · contact PI